Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

Ujjwal Neogi, Anders Sönnerborg, Stefan G. Sarafianos, Siddappa N. Byrareddy, Kamal Singh, Xiao Heng, Thomas P. Quinn, Anoop T. Ambikan, Kyle J. Hill

Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.

2020

coronavirus, RNA polymerase, MERS-CoV, SARS-CoV, SARS-CoV-2, COVID-19

DOI: 10.3390/pathogens9050320

Pathogens

MDPI AG

Medicine